Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

201931 citationsJournal Articlehybrid Open Access

Authors

Francisco J. Esteva · NYU Langone Health

Y. Baranau · Belarusian State Medical University

V. Baryash · Belarusian State Medical University

Alexey Manikhas · City Clinical Oncology Center

Vladimir Moiseyenko · State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care

Giorgi Dzagnidze

Edvard Zhavrid · N.N. Alexandrov National Cancer Centre

Abstract

Adjuvant CT-P6 demonstrated comparable efficacy and safety to trastuzumab at 1 year in patients with HER2-positive EBC, supporting CT-P6 and trastuzumab comparability.

Topics & Keywords

HER2/EGFR in Cancer Research Monoclonal and Polyclonal Antibodies Research Radiopharmaceutical Chemistry and Applications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Chemotherapy and Pharmacology

Volume 84, Issue 4, pp. 839-847

DOI: 10.1007/s00280-019-03920-4

Field-Weighted Citation Impact: 1.92